Axsome Therapeutics (AXSM) Metrics: History & Chart

Axsome Therapeutics, Inc.(AXSM)

Biotechnology · New York City, NY

$170.45-6.63 (-3.75%)

Delayed quote: Oct 6, 2026, 10:45 AM EDT

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.

New York City, NY

1,346 employees

www.axsome.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Herriot Tabuteau

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-8.67%
30D Total Return	-14.32%
YTD Total Return	-3.04%
1Y Total Return	+47.20%
3Y Total Return	+162.87%
5Y Total Return	+465.12%
10Y Total Return	+2025.85%
15Y Total Return	N/A
20Y Total Return	N/A

2026	-3.04%
2025	+115.86%
2024	+6.31%
2023	+3.19%
2022	+104.16%
2021	-53.63%
2020

CAGR TTM	+46.93%
CAGR 3Y	+38.00%
CAGR 5Y	+41.40%
CAGR 10Y	+35.76%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

AXSM Valuation Metrics

AXSM Stock Price Metrics

AXSM Dividend Metrics

AXSM Growth Rate Metrics

AXSM Discounted Cash Flow Metrics

AXSM Returns By Period

AXSM Yearly Returns

AXSM Average Annual Returns By Period (CAGR)

AXSM Revenue Metrics

AXSM PE Ratio Metrics

AXSM PS Ratio Metrics

AXSM PB Ratio Metrics

AXSM Price to Free Cash Flow Ratio Metrics

AXSM Debt to Equity Ratio Metrics

AXSM PEG Ratio Metrics

AXSM FCF Yield

AXSM Earnings Yield

AXSM EBITDA Yield

AXSM OCF Yield

AXSM EV/EBIT Ratio Metrics

AXSM EV/EBITDA Ratio Metrics

AXSM EV/Assets Ratio Metrics

AXSM EV/Sales Ratio Metrics

AXSM Current Ratio Metrics

AXSM Quick Ratio Metrics

AXSM ROIC Metrics

AXSM Return on Assets Metrics

AXSM Return on Equity Metrics

AXSM Net Profit Margin Metrics

AXSM Gross Profit Margin Metrics

AXSM Tax Rate Metrics

PS Ratio	11.74
PS Ratio Avg TTM	14.70
PS Ratio Avg 3Y	14.32
Current VS TTM Avg	-20.15%
Current VS 3Y Avg	-18.01%
Current VS 5Y Avg	-22.40%

PB Ratio	109.48
PB Ratio Avg TTM	137.84
PB Ratio Avg 3Y	69.63
Current VS TTM Avg	-20.57%
Current VS 3Y Avg	+57.23%
Current VS 5Y Avg	+77.73%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	2.63
Debt/Equity Ratio Avg TTM	3.07
Debt/Equity Ratio Avg 3Y	2.33
Current VS TTM Avg	-14.18%
Current VS 3Y Avg	+13.04%
Current VS 5Y Avg	+15.81%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	11.84
Ev/Assets Ratio Avg TTM	13.44
Ev/Assets Ratio Avg 3Y	9.39
Current VS TTM Avg	-11.88%
Current VS 3Y Avg	+26.15%
Current VS 5Y Avg	+25.64%

Ev/Sales Ratio	11.61
Ev/Sales Ratio Avg TTM	14.55
Ev/Sales Ratio Avg 3Y	13.92
Current VS TTM Avg	-20.23%
Current VS 3Y Avg	-16.57%
Current VS 5Y Avg	-20.75%

Current Ratio	1.43
Current Ratio Avg TTM	1.50
Current Ratio Avg 3Y	2.49
Current VS TTM Avg	-5.06%
Current VS 3Y Avg	-42.75%
Current VS 5Y Avg	-52.26%

Quick Ratio	1.34
Quick Ratio Avg TTM	1.43
Quick Ratio Avg 3Y	2.41
Current VS TTM Avg	-6.20%
Current VS 3Y Avg	-44.30%
Current VS 5Y Avg	-53.97%

ROIC	(50.82%)
ROIC Avg 3Y	(60.87%)
ROIC Avg 5Y	(68.29%)
Current VS 3Y Avg	+16.51%
Current VS 5Y Avg	+25.59%
Current VS 10Y Avg	+29.47%

ROA	(25.17%)
ROA Avg TTM	(6.90%)
ROA Avg 3Y	(10.32%)
Current VS TTM Avg	-265.01%
Current VS 3Y Avg	-143.78%
Current VS 5Y Avg	-95.83%

ROE	(230.05%)
ROE Avg TTM	(286.33%)
ROE Avg 3Y	(274.25%)
Current VS TTM Avg	+19.66%
Current VS 3Y Avg	+16.12%
Current VS 5Y Avg	+6.58%

Net Profit Margin	(24.68%)
Net Profit Margin Avg TTM	(26.28%)
Net Profit Margin Avg 3Y	(67.43%)
Current VS TTM Avg	+6.10%
Current VS 3Y Avg	+63.40%
Current VS 5Y Avg	+50.00%

Gross Profit Margin	93.24%
Gross Pft Margin Avg TTM	92.77%
Gross Pft Margin Avg 3Y	91.52%
Current VS TTM Avg	+0.50%
Current VS 3Y Avg	+1.88%
Current VS 5Y Avg	+2.27%

Tax Rate	0.29%
Tax Rate Avg 3Y	(0.04%)
Tax Rate Avg 5Y	(0.02%)
Current VS 3Y Avg	+928.57%
Current VS 5Y Avg	+1342.86%
Current VS 10Y Avg	+124.50%